Table 2.
Regression analysis for predicting factors associated with change of best-corrected visual acuity at 1 year in neovascular age-related macular degeneration treated with ranibizumab or aflibercept.
| Coefficient | P-value | Adjusted for age, sex, baseline BCVA | P-value | |
|---|---|---|---|---|
| Age | 0.002 | 0.590 | 0.003 | 0.458 |
| Sex (male = 1) | −0.017 | 0.823 | −0.019 | 0.809 |
| Drug type (aflibercept = 1) | −0.024 | 0.754 | −0.018 | 0.822 |
| Baseline BCVA | −0.202 | 0.085 | −0.271 | 0.028 |
| Baseline CFT | 0.001 | 0.109 | 0.001 | 0.046 |
| ERM at baseline | 0.117 | 0.317 | 0.081 | 0.504 |
| SRF at baseline | −0.070 | 0.411 | −0.085 | 0.316 |
| IRC at baseline | 0.031 | 0.714 | 0.004 | 0.964 |
| PED at baseline | 0.167 | 0.031 | 0.205 | 0.009 |
| Disrupted ELM at baseline | 0.182 | 0.020 | 0.236 | 0.003 |
| Disrupted EZ at baseline | 0.018 | 0.859 | 0.107 | 0.325 |
| ERM at month 12 | 0.094 | 0.380 | 0.066 | 0.562 |
| SRF at month 12 | 0.150 | 0.055 | 0.116 | 0.159 |
| IRC at month 12 | 0.369 | <0.001 | 0.351 | <0.001 |
| PED at month 12 | 0.236 | 0.002 | 0.241 | 0.001 |
| Total injections | −0.017 | 0.513 | −0.020 | 0.428 |
BCVA = best-corrected visual acuity; CFT = central foveal thickness; ELM = external limiting membrane; ERM = epiretinal membrane; EZ = ellipsoid zone; IRC = intraretinal cyst; PED = pigment epithelial detachment; SRF = subretinal fluid. Bold text indicates a statistical significance with a p-value less than 0.05.